Conclusion First: Intentional data fabrication and publication falsification in medicine and laboratory medicine are not isolated incidents but rather documented systemic vulnerabilities. The most thoroughly documented cases involve not only individual fabricators but also the failure of institutional oversight, editorial processes, and peer review. The case of Prof. Axel M. Gressner and his son Olav Gressner at RWTH Aachen University illustrates a particularly instructive form of falsification: manipulation occurring at the galley proof stage, after peer review but before final publication. Other landmark cases—Joachim Boldt in anesthesiology and Yoshitaka Fujii in anesthesia—demonstrate industrial-scale fabrication, with retraction counts reaching into the hundreds.
The Gressner Case: Falsification at the Proof Stage
The Gressner case is notable not for its scale but for its mechanism. Axel M. Gressner was a senior professor at the Institute of Clinical Chemistry and Pathobiochemistry at RWTH University Hospital Aachen, and his son Olav A. Gressner was a researcher in the same institution. Their work focused on liver fibrosis and the potential protective effects of caffeine.
In 2009, the Journal of Hepatology published a Letter to the Editor by Olav Gressner, Monika Siluschek, Birgit Lahme, and Axel M. Gressner, titled „Intraperitoneal application of caffeine prevents D-galactosamine induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat“ . The letter reported experiments on rats.
The retraction notice, issued at the request of Editor-in-Chief Didier Samuel, is unusually explicit about what occurred. The manuscript originally submitted and accepted described four groups of five rats (twenty animals total). After acceptance, during the galley proof stage, the authors made major modifications without informing the editor. Specifically:
- The number of rats per group was reduced from 5 to 1, meaning only four rats total were studied, not twenty.
- Sentences throughout the manuscript were changed from „rats“ to „rat.“
- Standard deviation values were removed, and some results were completely altered.
- An entire paragraph was added at the end that was not present in the submitted version .
The editors concluded that „the authors have presented falsified results which misled the Editors“ and retracted the letter .
The response from the Gressner side was defiant. Axel Gressner wrote to Retraction Watch claiming that the changes had been approved by an Elsevier issue manager, who allegedly told them that additional editorial review was unnecessary . He characterized the retraction as „harsh, rigorous and dictatorial“ and suggested non-scientific motives on the editor’s part. The journal’s editor stated that the editors „were not convinced“ by the lab’s claim that „typewritten errors“ were to blame .
The institutional consequences were significant. RWTH Aachen University investigated Olav Gressner; he left the university and was no longer employed there . The journal Hepatology briefly posted an article by Olav Gressner online but withdrew it days later after learning of the fraud investigation, with managing editor Greg Bologna stating that „sufficient concerns were raised during the investigation about fraudulent data“ .
The Gressner case demonstrates a specific vulnerability in the publication pipeline: the proof stage, where substantive changes can be introduced after peer review has been completed and without triggering re-review.
The Boldt Case: Industrial-Scale Fabrication
Joachim Boldt, a German anesthesiologist formerly at Justus-Liebig University Giessen and later at Klinikum Ludwigshafen, represents the largest documented case of research fabrication in modern medicine by retraction count. As of 2026, his retraction total stands at 240, the highest on the Retraction Watch Leaderboard .
The scope of the fraud was systemic. An investigation by Klinikum Ludwigshafen found that in most of Boldt’s studies, patient documentation could not be found. Where records did exist, evidence of scientific fraud was also found . The State Medical Association of Rheinland-Pfalz determined that studies were conducted without Institutional Review Board approval, leading Anesthesia & Analgesia to retract 22 papers in 2011 . Subsequent institutional investigations found that Boldt’s studies „failed to meet required standards,“ included „false data“ in at least 10 studies, and found „clear evidence of procedural irregularities and research misconduct“ .
The retractions continued for over fifteen years. In February 2026 alone, the European Journal of Anaesthesiology retracted eight additional Boldt papers, including a 1987 study published while he was at Giessen. The university’s investigation recommended that „all articles where Joachim Boldt is the responsible author are retracted, even in the absence of explicit falsification“ . Journals including CHEST have also retracted decades-old Boldt papers based on the institutional findings .
The Fujii Case: Statistical Detection of Fabrication
Yoshitaka Fujii, a Japanese anesthesiologist, was found to have fabricated data on a scale comparable to Boldt. His case is notable for the role of statistical forensic analysis in detection. The retraction notices cite „overwhelming evidence of fabrication related to the fact that the distributions of many variables reported by Dr. Fujii in these studies are exceedingly unlikely“ . In other words, the data were too clean, too consistent, and too perfectly distributed to have arisen from real clinical experiments.
As with Boldt, Fujii’s institution could not attest to the integrity of the studies or the underlying data. The retractions were coordinated across multiple journals, including the Journal of Anesthesia and the Canadian Journal of Anesthesia .
Laboratory Medicine and the Pathology Dimension
The Gressner case is rooted in a clinical chemistry and pathobiochemistry laboratory, and the falsification involved animal experimental data rather than patient samples. However, laboratory medicine more broadly has seen significant misconduct cases involving fabricated or falsified laboratory data.
In the United States, the Office of Research Integrity (ORI) found that Janina Jiang, a researcher in UCLA’s Department of Pathology and Laboratory Medicine, „engaged in research misconduct by knowingly and recklessly“ falsifying flow cytometry data in 11 grant applications. The falsified data purported to represent interferon-? expression in immune cells of mice, but the represented data were „incompatible with the raw experimental data“ . Three of the eleven applications were funded, totaling $58.7 million, though Jiang’s contribution to the largest grant appears to have been minor .
In Canada, a high-profile case involving Sylvia Asa, former Program Medical Director of the Laboratory Medicine Program at University Health Network in Toronto—the largest hospital diagnostic laboratory in Canada—and her husband Shereen Ezzat resulted in retractions and a complex legal outcome. An investigation committee found numerous instances of fabrication and falsification over more than a decade, but could not determine exactly who was directly responsible for the image manipulations. An Ontario court set aside the finding that the researchers personally committed falsification while upholding a finding of material non-compliance . Three of their papers were retracted, and more than a dozen others were questioned on PubPeer .
Patterns and Vulnerabilities
Across these cases, several patterns emerge:
Post-acceptance manipulation. The Gressner case shows that falsification can occur after peer review, exploiting the proof stage where editors may not scrutinize changes closely.
Institutional failure and delay. In the Boldt case, the fabricator continued to publish for years, and retractions continue decades after the original studies. The institutions‘ investigations, while eventually thorough, were slow to initiate and slow to communicate findings to journals.
Statistical forensics as detection. The Fujii case demonstrates that fabricated data often exhibit statistical signatures—distributions that are too uniform or too perfect—that can be detected through forensic analysis even without access to raw data.
Image manipulation. In the Asa/Ezzat case and the ORI findings involving UCLA, duplicated or manipulated images were central to the misconduct. Laboratory medicine, with its reliance on gel electrophoresis, microscopy, and flow cytometry images, is particularly vulnerable to this form of falsification.
Accountability gaps. In several cases, institutions concluded that fabrication occurred but could not or did not identify individual culprits. The Asa/Ezzat case explicitly noted that the committee could not determine who was directly responsible, and the court subsequently set aside personal findings of falsification .
Sources
- Journal of Hepatology Retraction Notice: „Intraperitoneal application of caffeine prevents D-galactosamine induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat“
- Retraction Watch: „Liver spots: Hepatology journal yanks research letter on caffeine-fibrosis link, saying authors falsified data“ (2010)
- Retraction Watch: „Update: German university investigating authors who retracted caffeine-liver fibrosis letter“ (2010)
- Retraction Watch: „Retraction Count for Anesthesiologist Joachim Boldt Reaches 240“ (2026)
- Anesthesia & Analgesia: Editor’s Note, Notice of Retraction (2014)
- CHEST Journal: Retraction Notice for Boldt et al. articles
- Journal of Anesthesia (PubMed): Retraction note for Yoshitaka Fujii articles (2013)
- Canadian Journal of Anesthesia (Europe PMC): Retraction note for Fujii article (2012)
- Retraction Watch: „UCLA veteran researcher faked data in 11 grant applications, per Feds“ (2022)
- Retraction Watch: „Ontario court quashes part of misconduct finding for prominent pair“ (2016)
